On Nov 05, major Wall Street analysts update their ratings for $Verona Pharma (VRNA.US)$, with price targets ranging from $42 to $64.
Wells Fargo analyst Tiago Fauth maintains with a buy rating, and maintains the target price at $64.
Jefferies analyst Andrew Tsai maintains with a buy rating, and adjusts the target price from $38 to $45.
BTIG analyst Thomas Shrader maintains with a buy rating, and adjusts the target price from $34 to $51.
Truist Financial analyst Joon Lee maintains with a buy rating.
CCORF analyst Edward Nash maintains with a buy rating, and adjusts the target price from $37 to $44.
Furthermore, according to the comprehensive report, the opinions of $Verona Pharma (VRNA.US)$'s main analysts recently are as follows:
The company's sales in October were reported to surpass those in Q3, even before the acquisition of a permanent J-code and the potential inclusion in the GOLD guidelines. This not only indicates a promising near-term launch trajectory but also substantially lessens the risk of a launch 'fizzle'.
Verona Pharma's Q3 sales outperformed expectations, with a reported $5.6M surpassing the projected $2M. This performance, coupled with a novel mechanism of action, management's optimistic outlook for Q4 and beyond into 2025, and favorable evaluations, leads to the anticipation of increased sales momentum. This bolsters the prospects for what could become a leading COPD treatment.
Here are the latest investment ratings and price targets for $Verona Pharma (VRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月5日，多家华尔街大行更新了$维罗纳制药 (VRNA.US)$的评级，目标价介于42美元至64美元。
富国集团分析师Tiago Fauth维持买入评级，维持目标价64美元。
富瑞集团分析师Andrew Tsai维持买入评级，并将目标价从38美元上调至45美元。
BTIG分析师Thomas Shrader维持买入评级，并将目标价从34美元上调至51美元。
储亿银行分析师Joon Lee维持买入评级。
CCORF分析师Edward Nash维持买入评级，并将目标价从37美元上调至44美元。
此外，综合报道，$维罗纳制药 (VRNA.US)$近期主要分析师观点如下：
在维罗纳制药永久J码获取以及有望纳入GOLD指南之前，据报道该公司十月份的销售额已超过第三季度，这不仅显示了一个有前途的近期上市轨迹，而且大大降低了上市的风险。
维罗纳制药第三季度的销售表现超出预期，据报道销售额达到560万美元，超过了预期的200万美元。这一表现，加上新的作用机制、管理层对第四季度以及2025年以及之后的乐观前景，以及积极的评估，都预示着销售势头的提升。这加强了成为一种领先的COPD治疗药物的前景。
以下为今日6位分析师对$维罗纳制药 (VRNA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
